RSS-Feed abonnieren
DOI: 10.1055/s-0042-1750796
Hydroxocobalamin Treatment and Pediatric Migraine Disability Assessment Scale Scores


Abstract
Migraine is a common neurologic disorder in children, especially in adolescents. It can affect the school performance, family, and social daily activities. The Pediatric Migraine Disability Assessment Scale (PedMIDAS) is commonly used in young patients. This study evaluated vitamin B12 deficiency in children with migraine and the effect of hydroxocobalamin treatment on PedMIDAS scores. The study group comprised patients with vitamin B12 deficiency and diagnosed migraine. The PedMIDAS questionnaire was conducted before and 3 months after hydroxocobalamin treatment. PedMIDAS scores were evaluated and compared before and after hydroxocobalamin treatment. The mean ± standard deviation of vitamin B12 level was 175.9 ± 21.3 pg/mL in children with migraine. The PedMIDAS scores were significantly lower after hydroxocobalamin treatment than before treatment (p < 0.001). These results indicated that hydroxocobalamin made a positive contribution to the mitigation of migraine symptoms in children and that treating vitamin B12 deficiency could be a useful option.
Authors' Contributions
Surgical and medical practices: S.A. and C.D.; concept: S.A.; design: S.A.; data collection and/or processing: S.A. and C.D.; analysis or interpretation: S.A. and C.D.; literature search: S.A. and C.D.; and writing manuscript: S.A. and C.D.
Publikationsverlauf
Eingereicht: 20. Februar 2022
Angenommen: 18. Mai 2022
Artikel online veröffentlicht:
11. Juli 2022
© 2022. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany